Daiichi To Use Ranbaxy Buy To Enter Africa, East Europe
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo plans to expand into Eastern European and African markets by taking advantage of the network of Ranbaxy Laboratories, which Daiichi is acquiring. The Japanese company plans to own more than 50.1 percent of Ranbaxy by December, enabling it to apply for foreign drug-marketing authorizations. Many of its intended sales are generics for drugs about to lose patent protection, but it has not decided which of those to emphasize. The firm expects big sales from antibacterial agents for contagious diseases. Ranbaxy, based in Gurgaon, India, has a presence in 49 markets, Daiichi 20. (Click here for more - a subscription may be required